Bioinformatic identification of a fatty acid metabolism-related gene signature for prognosis prediction and drug sensitivity assessment in osteosarcoma

Introduction: Osteosarcoma is an aggressive malignancy with high metastatic potential, leading to poor prognosis in recurrent and metastatic cases. Objectives: This study aimed to identify prognostic fatty acid metabolism-related genes (FAMRGs) in osteosarcoma and characterize the clinical and biological features of ACSF2. Methods: Transcriptomic and clinical data from Therapeutically Applicable Research to Generate Effective Treatments–Osteosarcoma, Genotype-Tissue Expression, and GSE16088 were analyzed. Consistently differentially expressed FAMRGs were screened via dual-cohort validation. Least absolute shrinkage and selection operator and Cox regression analyses were used to select prognostic genes, with overall survival (OS) as the primary endpoint and event-free survival (EFS) as the secondary endpoint. An ACSF2-based prognostic model combined with metastatic status was internally validated by bootstrap resampling. Gene Set Enrichment Analysis, OncoPredict, ESTIMATE, and CIBERSORT analyses were performed to explore ACSF2-associated pathways, drug sensitivity, and immune infiltration. In vitro functional assays were conducted to verify the biological function of acyl-CoA synthetase family member 2 (ACSF2). Results: Four prognostic FAMRGs were screened from 15 consistently dysregulated genes. Low ACSF2 expression independently predicted inferior OS and EFS, without significant correlation with diagnostic metastasis. The optimized model yielded a corrected C-index of 0.729 and a calibration slope of 0.943. ACSF2 was closely associated with fatty acid and mitochondrial metabolism. The ACSF2-high subgroup showed higher predicted sensitivity to Uprosertib and MN-64 and exhibited distinct immune infiltration patterns. Functional experiments confirmed that elevated ACSF2 expression suppresses the migration and invasion of human osteosarcoma cells. Conclusion: ACSF2 is a promising candidate prognostic biomarker for osteosarcoma. Its metabolic, pharmacological, and immune correlations are exploratory and require further experimental validation.

Authors

Institutions

Publication Details

Journal
Eurasian Journal of Medicine and Oncology
Published
2026-11-17
DOI
https://doi.org/10.36922/ejmo026310397
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bioinformatic identification of a fatty acid metabolism-related gene signature for prognosis prediction and drug sensitivity assessment in osteosarcoma

Chuanzhi Zhang, Changsheng Zhang, Hao Gu, Yu Li et al.
3 links
Eurasian Journal of Medicine and Oncology
Sarcoma Diagnosis and Treatment
article

Bioinformatic identification of a fatty acid metabolism-related gene signature for prognosis prediction and drug sensitivity assessment in osteosarcoma

Chuanzhi Zhang, Changsheng Zhang, Hao Gu, Yu Li, Xiao Shi, Xinxin Si
article en

Abstract

Introduction: Osteosarcoma is an aggressive malignancy with high metastatic potential, leading to poor prognosis in recurrent and metastatic cases. Objectives: This study aimed to identify prognostic fatty acid metabolism-related genes (FAMRGs) in osteosarcoma and characterize the clinical and biological features of ACSF2. Methods: Transcriptomic and clinical data from Therapeutically Applicable Research to Generate Effective Treatments–Osteosarcoma, Genotype-Tissue Expression, and GSE16088 were analyzed. Consistently differentially expressed FAMRGs were screened via dual-cohort validation. Least absolute shrinkage and selection operator and Cox regression analyses were used to select prognostic genes, with overall survival (OS) as the primary endpoint and event-free survival (EFS) as the secondary endpoint. An ACSF2-based prognostic model combined with metastatic status was internally validated by bootstrap resampling. Gene Set Enrichment Analysis, OncoPredict, ESTIMATE, and CIBERSORT analyses were performed to explore ACSF2-associated pathways, drug sensitivity, and immune infiltration. In vitro functional assays were conducted to verify the biological function of acyl-CoA synthetase family member 2 (ACSF2). Results: Four prognostic FAMRGs were screened from 15 consistently dysregulated genes. Low ACSF2 expression independently predicted inferior OS and EFS, without significant correlation with diagnostic metastasis. The optimized model yielded a corrected C-index of 0.729 and a calibration slope of 0.943. ACSF2 was closely associated with fatty acid and mitochondrial metabolism. The ACSF2-high subgroup showed higher predicted sensitivity to Uprosertib and MN-64 and exhibited distinct immune infiltration patterns. Functional experiments confirmed that elevated ACSF2 expression suppresses the migration and invasion of human osteosarcoma cells. Conclusion: ACSF2 is a promising candidate prognostic biomarker for osteosarcoma. Its metabolic, pharmacological, and immune correlations are exploratory and require further experimental validation.

Eurasian Journal of Medicine and OncologyVol. 0(0)
Lianyungang Runzhong Pharmaceutical (China) (CN)
National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon